# Johnson & Johnson

> Johnson & Johnson is a global healthcare company focused on Innovative Medicine and MedTech after separating Kenvue in 2023. It develops and sells prescription medicines, cardiovascular devices, surgical technologies, orthopaedic products and vision care through healthcare professionals and institutions.

- **Founded:** 1886
- **Headquarters:** New Brunswick, United States
- **Founders:** Robert Wood Johnson (Co-founder and first president), James Wood Johnson (Co-founder), Edward Mead Johnson (Co-founder)
- **Products:** Innovative Medicine, CARVYKTI, Impella, Shockwave intravascular lithotripsy, OTTAVA
- **Notable:** Built an early mass-production business around sterile surgical supplies., Published an antiseptic wound-treatment guide in 1888., Listed publicly in 1944.

## Products & services

- **Innovative Medicine** — Prescription medicines across oncology, immunology, neuroscience and cardiopulmonary disease; includes DARZALEX, STELARA and other therapies.
- **CARVYKTI** — CAR-T cell therapy co-developed with Legend Biotech for eligible adults with previously treated multiple myeloma; first FDA approval in 2022.
- **Impella** — Abiomed heart pumps for support in specified clinical settings; Abiomed joined J&J in 2022. Acquisition date is not a product launch date.
- **Shockwave intravascular lithotripsy** — Specialist catheter technology using acoustic pressure waves to fracture vascular calcium; acquired with Shockwave Medical in 2024.
- **OTTAVA** — Table-integrated robotic surgical system; J&J announced U.S. FDA market authorization in July 2026.
- **ACUVUE** — Prescription contact lens brand introduced in 1987.
- **MedTech surgical, orthopaedic and vision products** — Portfolio includes wound closure, surgical equipment, orthopaedic devices, electrophysiology and eye care technologies.

## Achievements

- Built an early mass-production business around sterile surgical supplies.
- Published an antiseptic wound-treatment guide in 1888.
- Listed publicly in 1944.
- CARVYKTI received initial FDA approval in February 2022.
- Completed Kenvue separation in August 2023.
- Reported $94.193 billion in fiscal 2025 sales.
- Announced U.S. FDA market authorization for OTTAVA in July 2026.

## Latest updates

- **2026-10** — October 13 third-quarter release reported sales of $25.399 billion, up 5.9%, and raised full-year reported-sales guidance to $101.2 billion at the midpoint. Guidance is a projection, not realized revenue.
- **2026-10** — The Q3 release reported a special charge for a proposed talc litigation resolution, alongside acquisition and collaboration effects on earnings.
- **2026-09** — FDA classified the Automated Impella Controller recall as Class I on September 24.
- **2026-07** — J&J announced U.S. FDA market authorization for the OTTAVA robotic surgical system on July 22.

## Links

- Website: https://www.jnj.com/
- LinkedIn: https://www.linkedin.com/company/johnson-&-johnson/
- Twitter/X: https://twitter.com/JNJNews
- YouTube: https://www.youtube.com/@jnj
- Instagram: https://www.instagram.com/jnj/
- Facebook: https://www.facebook.com/jnj/

---

Profile page: https://yespress.io/johnson-and-johnson
Published by YesPress — https://yespress.io
Last updated: 2026-10-22